In Vivo
Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.
Published in September 2005
Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.